Nf1 Loss and Ras Hyperactivation in Oligodendrocytes Induce NOS-Driven Defects in Myelin and Vasculature

Cell Reports

Volumn 4, Issue 6, 2013, Pages 1197-1212

  Mayes, Debra A ^a   Rizvi, Tilat A ^a   Titus Mitchell, Haley ^a   Oberst, Rachel ^a   Ciraolo, Georgianne M ^a   Vorhees, Charles V ^a   Robinson, Andrew P ^b   Miller, Stephen D ^b   Cancelas, Jose A ^a   Stemmer Rachamimov, Anat O ^c   Ratner, Nancy ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CLAUDIN 11; CONNEXIN 32; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MYELIN; NEUROFIBROMIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RAS PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORPUS CALLOSUM; DOWN REGULATION; GAP JUNCTION; HAPLOINSUFFICIENCY; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OLIGODENDROGLIA; OPTIC NERVE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; UPREGULATION;

MUS;

ANIMALS; BLOOD VESSELS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN SHEATH; NEUROFIBROMIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLIGODENDROGLIA; RAS PROTEINS;

EID: 84884590947     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.08.011     Document Type: Article

References (55)

1. Acosta M.T., Bearden C.E., Castellanos F.X., Cutting L., Elgersma Y., Gioia G., Gutmann D.H., Lee Y.S., Legius E., Muenke M., et al. The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am. J. Med. Genet. A. 2012, 158A:2225-2232.
2. Afzal F., Polak J., Buttery L. Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity. J.Pathol. 2004, 202:503-510.
3. Ahn M., Lee J., Gustafsson A., Enriquez A., Lancaster E., Sul J.Y., Haydon P.G., Paul D.L., Huang Y., Abrams C.K., Scherer S.S. Cx29 and Cx32, two connexins expressed by myelinating glia, do not interact and are functionally distinct. J.Neurosci. Res. 2008, 86:992-1006.
4. Angelow S., Ahlstrom R., Yu A.S. Biology of claudins. Am. J. Physiol. Renal. Physiol. 2008, 295:F867-F876.
5. Bennett M.R., Rizvi T.A., Karyala S., McKinnon R.D., Ratner N. Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. J.Neurosci. 2003, 23:7207-7217.
6. Beutheu Y.S., Belmonte L., Galas L., Boukhettala N., BÔle-Feysot C., Déchelotte P., Coëffier M. Methotrexate modulates tight junctions through NF-κB, MEK, and JNK pathways. J.Pediatr. Gastroenterol. Nutr. 2012, 54:463-470.
7. Brannan C.I., Perkins A.S., Vogel K.S., Ratner N., Nordlund M.L., Reid S.W., Buchberg A.M., Jenkins N.A., Parada L.F., Copeland N.G. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994, 8:1019-1029.
8. Chen Y., Curran C.P., Nebert D.W., Patel K.V., Williams M.T., Vorhees C.V. Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm-/- knockout mice. Neurotoxicol. Teratol. 2012, 34:450-457.
9. Chow E., Mottahedeh J., Prins M., Ridder W., Nusinowitz S., Bronstein J.M. Disrupted compaction of CNS myelin in an OSP/Claudin-11 and PLP/DM20 double knockout mouse. Mol. Cell. Neurosci. 2005, 29:405-413.
10. Daston M.M., Scrable H., Nordlund M., Sturbaum A.K., Nissen L.M., Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992, 8:415-428.
11. DiPaolo D.P., Zimmerman R.A., Rorke L.B., Zackai E.H., Bilaniuk L.T., Yachnis A.T. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995, 195:721-724.
12. Dlugosova K., Okruhlicova L., Mitasikova M., Sotnikova R., Bernatova I., Weismann P., Slezak J., Tribulova N. Modulation of connexin-43 by omega-3 fatty acids in the aorta of old spontaneously hypertensive rats. J.Physiol. Pharmacol. 2009, 60:63-69.
13. Doerflinger N.H., Macklin W.B., Popko B. Inducible site-specific recombination in myelinating cells. Genesis 2003, 35:63-72.
14. Dumont M., Stack C., Elipenahli C., Jainuddin S., Gerges M., Starkova N.N., Yang L., Starkov A.A., Beal F. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 2011, 25:4063-4072.
15. Ferro E., Goitre L., Retta S.F., Trabalzini L. The interplay between ROS and Ras GTPases: physiological and pathological implications. J.Signal Transduct. 2012, 2012:365769.
16. Gandhi G.K., Ball K.K., Cruz N.F., Dienel G.A. Hyperglycaemia and diabetes impair gap junctional communication among astrocytes. ASN Neuro 2010, 2:e00030.
17. Gysin S., Salt M., Young A., McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
18. Hegedus B., Dasgupta B., Shin J.E., Emnett R.J., Hart-Mahon E.K., Elghazi L., Bernal-Mizrachi E., Gutmann D.H. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors invivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 2007, 1:443-457.
19. Heimfarth L., Loureiro S.O., Pierozan P., de Lima B.O., Reis K.P., Torres E.B., Pessoa-Pureur R. Methylglyoxal-induced cytotoxicity in neonatal rat brain: a role for oxidative stress and MAP kinases. Metab. Brain Dis. 2013, 28:429-438.
20. Hyman S.L., Gill D.S., Shores E.A., Steinberg A., North K.N. T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J.Neurol. Neurosurg. Psychiatry 2007, 78:1088-1091.
21. Kamens H.M., Crabbe J.C. The parallel rod floor test: a measure of ataxia in mice. Nat. Protoc. 2007, 2:277-281.
22. Karlsgodt K.H., Rosser T., Lutkenhoff E.S., Cannon T.D., Silva A., Bearden C.E. Alterations in white matter microstructure in neurofibromatosis-1. PLoS ONE 2012, 7:e47854.
23. Kim K.Y., Ju W.K., Hegedus B., Gutmann D.H., Ellisman M.H. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience 2010, 170:178-188.
24. Komatsu T., Ireland D.D., Chung N., Doré A., Yoder M., Reiss C.S. Regulation of the BBB during viral encephalitis: roles of IL-12 and NOS. Nitric Oxide 1999, 3:327-339.
25. Lee K.M., Kwon J.Y., Lee K.W., Lee H.J. Ascorbic acid 6-palmitate suppresses gap-junctional intercellular communication through phosphorylation of connexin 43 via activation of the MEK-ERK pathway. Mutat. Res. 2009, 660:51-56.
26. Li W., Cui Y., Kushner S.A., Brown R.A., Jentsch J.D., Frankland P.W., Cannon T.D., Silva A.J. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 2005, 15:1961-1967.
27. Li X., Newbern J.M., Wu Y., Morgan-Smith M., Zhong J., Charron J., Snider W.D. MEK is a key regulator of gliogenesis in the developing brain. Neuron 2012, 75:1035-1050.
28. Magnotti L.M., Goodenough D.A., Paul D.L. Deletion of oligodendrocyte Cx32 and astrocyte Cx43 causes white matter vacuolation, astrocyte loss and early mortality. Glia 2011, 59:1064-1074.
29. Mayes D.A., Rizvi T.A., Cancelas J.A., Kolasinski N.T., Ciraolo G.M., Stemmer-Rachamimov A.O., Ratner N. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res. 2011, 71:4675-4685.
30. Patel A.V., Eaves D., Jessen W.J., Rizvi T.A., Ecsedy J.A., Qian M.G., Aronow B.J., Perentesis J.P., Serra E., Cripe T.P., et al. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin. Cancer Res. 2012, 18:5020-5030.
31. Perilongo G., Opocher E., Viscardi E. Optic, hypothalamic, and thalamic tumors. Handb. Clin. Neurol. 2012, 105:607-613.
32. Pride N., Payne J.M., Webster R., Shores E.A., Rae C., North K.N. Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J.Child Neurol. 2010, 25:834-841.
33. Pummi K.P., Aho H.J., Laato M.K., Peltonen J.T., Peltonen S.A. Tight junction proteins and perineurial cells in neurofibromas. J.Histochem. Cytochem. 2006, 54:53-61.
34. Radosinska J., Bacova B., Bernatova I., Navarova J., Zhukovska A., Shysh A., Okruhlicova L., Tribulova N. Myocardial NOS activity and connexin-43 expression in untreated and omega-3 fatty acids-treated spontaneously hypertensive and hereditary hypertriglyceridemic rats. Mol. Cell. Biochem. 2011, 347:163-173.
35. Robertson C.A., Green B.G., Niedzwiecki L., Harrison R.K., Grant S.K. Effect of nitric oxide synthase substrate analog inhibitors on rat liver arginase. Biochem. Biophys. Res. Commun. 1993, 197:523-528.
36. Saura M., Tarin C., Zaragoza C. Recent insights into the implication of nitric oxide in osteoblast differentiation and proliferation during bone development. ScientificWorldJournal 2010, 10:624-632.
37. Segretain D., Falk M.M. Regulation of connexin biosynthesis, assembly, gap junction formation, and removal. Biochim. Biophys. Acta 2004, 1662:3-21.
38. Selek S., Bulut M., Ocak A.R., Kalenderoǧlu A., Savaş H.A. Evaluation of total oxidative status in adult attention deficit hyperactivity disorder and its diagnostic implications. J.Psychiatr. Res. 2012, 46:451-455.
39. Skelton M.R., Schaefer T.L., Graham D.L., Degrauw T.J., Clark J.F., Williams M.T., Vorhees C.V. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS ONE 2011, 6:e16187.
40. Simard M., Arcuino G., Takano T., Liu Q.S., Nedergaard M. Signaling at the gliovascular interface. J.Neurosci. 2003, 23:9254-9262.
41. Solga A.C., Gianino S.M., Gutmann D.H. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene 2013, Published online January 14, 2013. 10.1038/onc.2012.580.
42. Taniguchi Ishikawa E., Gonzalez-Nieto D., Ghiaur G., Dunn S.K., Ficker A.M., Murali B., Madhu M., Gutstein D.E., Fishman G.I., Barrio L.C., Cancelas J.A. Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells. Proc. Natl. Acad. Sci. USA 2012, 109:9071-9076.
43. Tiboni G.M., Giampietro F., Di Giulio C. The nitric oxide synthesis inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME) causes limb defects in mouse fetuses: protective effect of acute hyperoxia. Pediatr. Res. 2003, 54:69-76.
44. Tidyman W.E., Rauen K.A. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev. Mol. Med. 2008, 10:e37.
45. Tong J.J., Schriner S.E., McCleary D., Day B.J., Wallace D.C. Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster. Nat. Genet. 2007, 39:476-485.
46. van Engelen S.J., Krab L.C., Moll H.A., de Goede-Bolder A., Pluijm S.M., Catsman-Berrevoets C.E., Elgersma Y., Lequin M.H. Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging. AJNR Am. J. Neuroradiol. 2008, 29:816-822.
47. Vega Rasgado L.A., Ceballos Reyes G.M., Vega-Diaz M.F. Anticonvulsant drugs, oxidative stress and nitric oxide. Proc. West. Pharmacol. Soc. 2011, 54:41-48.
48. Viosca J., Schuhmacher A.J., Guerra C., Barco A. Germline expression of H-Ras(G12V) causes neurological deficits associated to Costello syndrome. Genes Brain Behav. 2009, 8:60-71.
49. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
50. Wang Y., Kim E., Wang X., Novitch B.G., Yoshikawa K., Chang L.S., Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell 2012, 150:816-830.
51. Williams V.C., Lucas J., Babcock M.A., Gutmann D.H., Korf B., Maria B.L. Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.
52. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 2002, 38:323-337.
53. Zatorre R.J., Fields R.D., Johansen-Berg H. Plasticity in gray and white: neuroimaging changes in brain structure during learning. Nat. Neurosci. 2012, 15:528-536.
54. Zeger M., Popken G., Zhang J., Xuan S., Lu Q.R., Schwab M.H., Nave K.A., Rowitch D., D'Ercole A.J., Ye P. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal invivo oligodendrocyte development and myelination. Glia 2007, 55:400-411.
55. Zhang J.H., Kawashima S., Yokoyama M., Huang P., Hill C.E. Increased eNOS accounts for changes in connexin expression in renal arterioles during diabetes. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 2006, 288:1000-1008.